Search clinical trials for: Safinamide

Total 41 results

Zambon SpA

Completed

A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese Volunteers

Healthy

China
Zambon SpA

Completed

Safinamide for Multiple System Atrophy (MSA)

Multiple System Atrophy

Italy, Spain
Zambon SpA

Withdrawn

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

Parkinson Disease | Dyskinesia, Drug-Induced
Alain Kaelin
Clinical Trial Unit Ente Ospedaliero Cantonale

Recruiting

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Idiopathic Parkinson's Disease (at Later Stage)

Switzerland
Newron Pharmaceuticals SPA

Completed

Safinamide Renal Impairment Trial

Renal Impairment

Germany
Supernus Pharmaceuticals, Inc.

Completed

Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (PRO-Go)

Idiopathic Parkinson Disease

United States
Zambon SpA

Completed

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Idiopathic Parkinson Disease

Spain, Austria, Italy, Germany, France
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Parkinson's Disease
Newron Pharmaceuticals SPA

Terminated

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Parkinson's Disease

Romania
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Hepatic Impairment

Germany
Newron Pharmaceuticals SPA

Terminated

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Parkinson Disease

United States
Newron Pharmaceuticals SPA

Completed

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Idiopathic Parkinson's Disease
Newron Pharmaceuticals SPA

Completed

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Parkinson's Disease With Cognitive Impairments

Spain, United States
IRCCS San Raffaele Roma

Completed

Overnight Switch From Rasagiline To Safinamide (SWH-MAOB)

Parkinson Disease

Italy
Zambon SpA

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Parkinson Disease

China
Newron Pharmaceuticals SPA

Completed

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Parkinson's Disease
Newron Pharmaceuticals SPA
Parexel; CliniRx

Completed

Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain

Pain

United Kingdom
Newron Pharmaceuticals SPA

Completed

Phase II Dose Titration Study in Patients With Neuropathic Pain

Neuropathic Pain

United Kingdom, Czech Republic, Poland, Italy, India, Austria
Newron Pharmaceuticals SPA

Completed

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects (Safinamide-LID)

Parkinson's Disease

Austria, Canada, France, Germany, South Africa
Newron Pharmaceuticals SPA

Completed

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Parkinson's Disease
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Newron Pharmaceuticals SPA

Terminated

MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918) (MOTION)

Idiopathic Parkinson's Disease

Switzerland
Eisai Limited

Completed

A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)

Lennox-Gastaut Syndrome

Japan
Wuhan Union Hospital, China

Completed

Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects

Seizures
Newron Pharmaceuticals SPA

Completed

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa (SETTLE)

Idiopathic Parkinson's Disease

Korea, Republic of, Israel, Thailand, New Zealand, Spain, Canada, United States, Switzerland, Netherlands, Taiwan, United Kingdom, Belgium, Estonia, Germany, Hungary, India, Australia, Austria, France, Malaysia, Slovakia
Newron Pharmaceuticals SPA

Completed

A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics

Idiopathic Parkinson's Disease

Italy
Eisai Inc.

Available

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome

Poland
Eisai Co., Ltd.

Completed

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome

Japan
Eisai Co., Ltd.

Completed

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Lennox-Gastaut Syndrome

Japan
Universita di Verona
Azienda Ospedaliera Universitaria Integrata Verona

Unknown

Pain in Parkinson's Disease With Motor Fluctuations. (PAINinPD)

Parkinson Disease

Italy
Eisai Inc.

Terminated

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Refractory Partial Onset Seizures

United States
Biotie Therapies Inc.
Syneos Health

Completed

Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

United States
Eisai Inc.

Completed

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Epilepsy

United States
University of South Alabama

Withdrawn

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

Refractory Partial Seizures

United States
Eisai Inc.

Completed

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Lennox-Gastaut Syndrome

France, Poland, United States, South Africa, Italy, Canada, Greece
University of Zurich

Withdrawn

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome (RUFPTPS)

Pain | Peripheral Nerve Injuries

Switzerland
Zambon SpA
Cross Research S.A.

Completed

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

Healthy

Switzerland
Cross Research S.A.
Zambon SpA

Completed

Safinamide Steady State Interaction With Rosuvastatin

Healthy

Switzerland
Newron Pharmaceuticals SPA

Completed

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

Idiopathic Parkinson's Disease

United States, Spain, Brazil, Peru, Colombia, Germany, Argentina, India, Croatia, Czech Republic, Italy, South Africa, Finland, Portugal, Canada, Slovakia, Bulgaria, Chile, Mexico, Poland
Assistance Publique - Hôpitaux de Paris

Recruiting

Population Pharmacokinetics of Antiepileptic in Pediatrics (EPIPOP)

Epilepsy

France
University College, London
The Leeds Teaching Hospitals NHS Trust; Cambridge University Hospitals NHS... and other collaborators

Unknown

Ketogenic Diet in Infants With Epilepsy (KIWE) (KIWE)

Epilepsy

United Kingdom

3

Subscribe